Peter Kalev
Bristol-Myers Squibb (Germany)(DE)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, DNA Repair Mechanisms, Cancer-related Molecular Pathways, Epigenetics and DNA Methylation, Cancer Genomics and Diagnostics
Most-Cited Works
- → p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity(2016)467 cited
- → MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage(2021)224 cited
- → EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma(2018)167 cited
- → Dephosphorylation Enables the Recruitment of 53BP1 to Double-Strand DNA Breaks(2014)133 cited
- → Loss of PPP2R2A Inhibits Homologous Recombination DNA Repair and Predicts Tumor Sensitivity to PARP Inhibition(2012)128 cited
- → p16INK4a Impairs Homologous Recombination–Mediated DNA Repair in Human Papillomavirus–Positive Head and Neck Tumors(2014)118 cited
- → RNF4 is required for DNA double-strand break repair in vivo(2012)118 cited
- → The deubiquitylase USP33 discriminates between RALB functions in autophagy and innate immune response(2013)99 cited
- → Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion(2021)91 cited
- → Protein Phosphatase 2A as a Potential Target for Anticancer Therapy(2011)57 cited